Company News
Zydus Saroglitazar Mg MASH Phase II(b) Trial Success
Zydus announced positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.
The trial met its primary endpoint with a 26.5% treatment difference for
